| Title | Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. | | Author(s) | Schwonzen M, Kurbacher CM, Mallmann P | | Institution | Department of Internal Medicine II, St Walburga-Hospital, Meschede, Germany. walburga.khs.edv@gmx.de | | Source | Anticancer Drugs 2000 Oct; 11(9):681-5. | | MeSH | Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Dose-Response Relationship, Drug
Doxorubicin
Drug Administration Schedule
Female
Humans
Liposomes
Middle Aged
Neoplasm Metastasis
Paclitaxel
Pilot Projects
Polyethylene Glycols
| | Abstract | The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure. Liposome-encapsulated doxorubicin is a new formulation of doxorubicin with no dose-limiting cardiac toxicity. Twenty-one patients with metastatic breast cancer were treated with pegylated liposomal doxorubicin (20 mg/m2, day 1) and paclitaxel (100 mg/m2, days 1 and 8) for six cycles every 2 weeks. All patients had had relapse or progression on one to five previous chemotherapies. We observed two patients with complete and eight patients with partial remissions (48% response rate). Eight of the 10 responders had had previous therapy with epirubicin, doxorubicin or mitoxantrone. The mean remission duration was 5 months. Disease progression due to brain metastasis occurred in five cases. Severe side effects (grade 3 WHO) were alopecia (100%), skin toxicity in 29%, neuropathy in 24% and mucositis in 13%. Leukopenia (grade 4 WHO) was observed in 48%, but there was no cardiac toxicity, no death and no hospitalization. The combination of weekly paclitaxel and liposomal doxorubicin every 2 weeks is highly effective in previously treated patients. Based on the doses we administered, we recommend 15 mg/m2 liposomal doxorubicin every 2 weeks and 80 mg/m2 paclitaxel weekly. | | Language | eng | | Pub Type(s) | Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
| | PubMed ID | 11129728 |
|
